Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Urology|April 19, 2011
Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancerDaniel A Barocas, Saundra Motley, Michael S Cookson, et al.
Prostate Cancer and Prostatic Diseases|April 14, 2019
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patientsEda K Holl, Megan A McNamara, Patrick Healy, et al.
The Prostate|August 12, 2020
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for cliniciansNeal D Shore, Charles G Drake, Daniel W Lin, et al.
Oncotarget|June 2, 2018
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarkerRachel A Levin, Maria E Lund, Quach Truong, et al.
The Journal of Urology|October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical DataE David Crawford, Jason M Hafron, Scott T Tagawa, et al.
Urology|March 18, 2017
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)E David Crawford, Daniel P Petrylak, Neal Shore, et al.
Urologic Oncology|April 20, 2020
Development and evaluation of the MiCheck test for aggressive prostate cancerNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
The Journal of Urology|August 6, 2018
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III)E David Crawford, Phillip J Koo, Neal Shore, et al.
Urologic Oncology|May 4, 2020
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trialNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
The Journal of Urology|October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical DataE David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Pageof 3